We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
+38.56%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$219M
AUM Growth
+$39.4M
(+22%)
Cap. Flow
-$5.93M
Cap. Flow
% of AUM
-2.71%
Top 10 Holdings %
Top 10 Hldgs %
60.99%
Holding
47
New
12
Increased
12
Reduced
11
Closed
10
Top Buys
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$7.8M |
| 2 |
AnaptysBio
ANAB
|
+$5.55M |
| 3 |
Envista
NVST
|
+$4.69M |
| 4 |
Organogenesis Holdings
ORGO
|
+$3.92M |
| 5 |
Aldeyra Therapeutics
ALDX
|
+$3.69M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
+$17M |
| 2 |
HNGR
Hanger Inc.
HNGR
|
+$8.05M |
| 3 |
uniQure
QURE
|
+$5.02M |
| 4 |
Humana
HUM
|
+$3.07M |
| 5 |
AbbVie
ABBV
|
+$2.95M |
Sector Composition
| 1 | Healthcare | 98.09% |
| 2 | Industrials | 1.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$17.4B
| $19.5M | 8.9% |
133,900
+2,060
| +2% | +$284K |
|
|
2
uniQure
QURE
$2.82B
| $17M | 7.78% |
237,500
-91,478
| -28% | -$5.02M |
|
|
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $14.9M | 6.82% |
328,129
+164,996
| +101% | +$7.8M |
|
4
Kura Oncology
KURA
$1.01B
| $14.2M | 6.51% |
1,036,000
+147,848
| +17% | +$2.19M |
|
5
United Therapeutics
UTHR
$22.6B
| $14.2M | 6.49% |
161,195
+28,258
| +21% | +$2.49M |
|
|
RETA
6
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $12.9M | 5.88% |
62,900
+309
| +0.5% | +$56.4K |
|
7
Iovance Biotherapeutics
IOVA
$2.12B
| $10.8M | 4.92% |
388,600
+42,451
| +12% | +$966K |
|
8
AC Immune
ACIU
$240M
| $10.6M | 4.84% |
1,242,843
-5,610
| -0.4% | -$37.4K |
|
9
MeiraGTx Holdings
MGTX
$1.16B
| $10.4M | 4.74% |
517,844
+179,748
| +53% | +$3.08M |
|
|
ARQL
10
DELISTED
Arqule Inc
ARQL
| $8.99M | 4.11% |
450,326
+85,529
| +23% | +$992K |
|
11
Centene
CNC
$32.9B
| $8.98M | 4.11% |
142,800
-22,200
| -13% | -$1.2M |
|
|
12
Aldeyra Therapeutics
ALDX
$116M
| $8.3M | 3.79% |
1,428,277
+638,049
| +81% | +$3.69M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.4B
| $7.84M | 3.59% |
92,737
+2,785
| +3% | +$210K |
|
14
UroGen Pharma
URGN
$1.94B
| $7.26M | 3.32% |
217,686
-107,699
| -33% | -$2.94M |
|
|
ALBO
15
DELISTED
Albireo Pharma Inc
ALBO
| $6.28M | 2.87% |
247,178
-5,322
| -2% | -$106K |
|
|
16
Envista
NVST
$4.35B
| $4.89M | 2.24% |
+165,000
| New | +$4.69M |
|
17
Personalis
PSNL
$1.65B
| $4.43M | 2.03% |
406,673
+291,459
| +253% | +$3.03M |
|
|
18
AnaptysBio
ANAB
$1.65B
| $3.82M | 1.75% |
+234,823
| New | +$5.55M |
|
19
Immunovant
IMVT
$8.19B
| $3.57M | 1.63% |
+224,702
| New | +$2.52M |
|
|
20
Organogenesis Holdings
ORGO
$320M
| $2.97M | 1.36% |
+617,836
| New | +$3.92M |
|
21
Evolus
EOLS
$392M
| $2.88M | 1.32% |
+236,939
| New | +$3.34M |
|
22
Gyre Therapeutics
GYRE
$731M
| $2.67M | 1.22% |
52,253
-22,168
| -30% | -$929K |
|
|
SBBP
23
DELISTED
Strongbridge Biopharma plc.
SBBP
| $2.63M | 1.2% |
1,258,224
-1,256,848
| -50% | -$2.41M |
|
|
RCM
24
DELISTED
R1 RCM Inc. Common Stock
RCM
| $2.6M | 1.19% |
200,000
-208,958
| -51% | -$2.39M |
|
25
Evolent Health
EVH
$660M
| $2.53M | 1.16% |
+279,390
| New | +$2.27M |
|
Similar funds
PL
BFC
ACM
FFWA
SAM
CBB
AIG
IA